Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00685399 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of AIN457 in Noninfectious Uveitis
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 76
- Enrollment target
NCT00685399 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 76 participants.
The verdict
NCT00685399, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 76 participants
- Enrollment target
Study Summary
This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
Interventions
- DRUG AIN457
- DRUG AIN 457
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 76 participants |
| Start Date | 2008-06 |
| Est. Completion | 2013-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00685399
The ClinicalTrials.gov registry entry for NCT00685399 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 76 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which AIN457 is the first listed.
NCT00685399 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00685399 about?
NCT00685399 is a clinical study titled "Safety and Efficacy of AIN457 in Noninfectious Uveitis". This study was performed to evaluate the efficacy and safety of AIN457 for patients with active uveitis that requires systemic immunosuppression.
What is the current status of trial NCT00685399?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 76 participants. The study started on 2008-06. Estimated completion is 2013-09.
What interventions are being tested in trial NCT00685399?
The interventions under investigation include: AIN457 (DRUG), AIN 457 (DRUG).
Who is sponsoring clinical trial NCT00685399?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.